Silber Sigmund, Albertsson Per, Avilés Francisco F, Camici Paolo G, Colombo Antonio, Hamm Christian, Jørgensen Erik, Marco Jean, Nordrehaug Jan-Erik, Ruzyllo Witold, Urban Philip, Stone Gregg W, Wijns William
Kardiologische Praxis und Praxisklinik, München, Germany.
Eur Heart J. 2005 Apr;26(8):804-47. doi: 10.1093/eurheartj/ehi138. Epub 2005 Mar 15.
In patients with stable CAD, PCI can be considered a valuable initial mode of revascularization in all patients with objective large ischaemia in the presence of almost every lesion subset, with only one exception: chronic total occlusions that cannot be crossed. In early studies, there was a small survival advantage with CABG surgery compared with PCI without stenting. The addition of stents and newer adjunctive medications improved the outcome for PCI. The decision to recommend PCI or CABG surgery will be guided by technical improvements in cardiology or surgery, local expertise, and patients' preference. However, until proved otherwise, PCI should be used only with reservation in diabetics with multi-vessel disease and in patients with unprotected left main stenosis. The use of drug-eluting stents might change this situation. Patients presenting with NSTE-ACS (UA or NSTEMI) have to be stratified first for their risk of acute thrombotic complications. A clear benefit from early angiography (<48 h) and, when needed, PCI or CABG surgery has been reported only in the high-risk groups. Deferral of intervention does not improve outcome. Routine stenting is recommended on the basis of the predictability of the result and its immediate safety. In patients with STEMI, primary PCI should be the treatment of choice in patients presenting in a hospital with PCI facility and an experienced team. Patients with contra-indications to thrombolysis should be immediately transferred for primary PCI, because this might be their only chance for quickly opening the coronary artery. In cardiogenic shock, emergency PCI for complete revascularization may be life-saving and should be considered at an early stage. Compared with thrombolysis, randomized trials that transferred the patients for primary PCI to a 'heart attack centre' observed a better clinical outcome, despite transport times leading to a significantly longer delay between randomization and start of the treatment. The superiority of primary PCI over thrombolysis seems to be especially clinically relevant for the time interval between 3 and 12 h after onset of chest pain or other symptoms on the basis of its superior preservation of myocardium. Furthermore, with increasing time to presentation, major-adverse-cardiac-event rates increase after thrombolysis, but appear to remain relatively stable after primary PCI. Within the first 3 h after onset of chest pain or other symptoms, both reperfusion strategies seem equally effective in reducing infarct size and mortality. Therefore, thrombolysis is still a viable alternative to primary PCI, if it can be delivered within 3 h after onset of chest pain or other symptoms. Primary PCI compared with thrombolysis significantly reduced stroke. Overall, we prefer primary PCI over thrombolysis in the first 3 h of chest pain to prevent stroke, and in patients presenting 3-12 h after the onset of chest pain, to salvage myocardium and also to prevent stroke. At the moment, there is no evidence to recommend facilitated PCI. Rescue PCI is recommended, if thrombolysis failed within 45-60 min after starting the administration. After successful thrombolysis, the use of routine coronary angiography within 24 h and PCI, if applicable, is recommended even in asymptomatic patients without demonstrable ischaemia to improve patients' outcome. If a PCI centre is not available within 24 h, patients who have received successful thrombolysis with evidence of spontaneous or inducible ischaemia before discharge should be referred to coronary angiography and revascularized accordingly--independent of 'maximal' medical therapy.
在稳定性冠心病患者中,对于几乎所有病变亚组中存在客观大面积缺血的所有患者,PCI可被视为一种有价值的初始血运重建方式,但有一个例外:无法通过的慢性完全闭塞病变。在早期研究中,与未植入支架的PCI相比,CABG手术有较小的生存优势。支架和新型辅助药物的应用改善了PCI的疗效。推荐PCI或CABG手术的决策将受心脏病学或外科技术进展、当地专业水平以及患者偏好的指导。然而,在未被证明有其他情况之前,多支血管病变的糖尿病患者和无保护左主干狭窄患者应谨慎使用PCI。药物洗脱支架的应用可能会改变这种情况。出现非ST段抬高型急性冠脉综合征(UA或NSTEMI)的患者必须首先根据其急性血栓形成并发症的风险进行分层。仅在高危组中报道了早期血管造影(<48小时)以及必要时PCI或CABG手术有明显益处。延迟干预并不能改善预后。基于结果的可预测性及其即时安全性,建议进行常规支架置入。在STEMI患者中,对于在有PCI设备和经验丰富团队的医院就诊的患者,直接PCI应作为首选治疗方法。有溶栓禁忌证的患者应立即转至行直接PCI,因为这可能是他们迅速开通冠状动脉的唯一机会。在心源性休克中,进行紧急PCI实现完全血运重建可能挽救生命,应尽早考虑。与溶栓相比,将患者转至“心脏病发作中心”进行直接PCI的随机试验观察到更好的临床结果,尽管转运时间导致随机分组至开始治疗之间的延迟显著延长。基于其对心肌的更好保护,直接PCI优于溶栓在胸痛或其他症状发作后3至12小时的时间间隔内似乎在临床上尤其相关。此外,随着就诊时间的增加,溶栓后主要不良心脏事件发生率增加,但直接PCI后似乎保持相对稳定。在胸痛或其他症状发作后的前3小时内,两种再灌注策略在减少梗死面积和死亡率方面似乎同样有效。因此,如果能在胸痛或其他症状发作后3小时内进行溶栓,溶栓仍是直接PCI的可行替代方法。与溶栓相比,直接PCI显著降低了卒中发生率。总体而言,我们在胸痛的前3小时更倾向于直接PCI以预防卒中,在胸痛发作后3 - 12小时就诊的患者中,更倾向于直接PCI以挽救心肌并预防卒中。目前,没有证据推荐易化PCI。如果溶栓在开始给药后45 - 60分钟内失败,建议进行补救PCI。溶栓成功后,即使在无症状且无明显缺血的患者中,也建议在24小时内进行常规冠状动脉造影并在适用时进行PCI以改善患者预后。如果24小时内没有PCI中心,在出院前有自发或诱发性缺血证据且溶栓成功的患者应转诊进行冠状动脉造影并相应地进行血运重建——与“最大程度”的药物治疗无关。